MX9605809A - Nuevos esteres lipidicos de monofosfatos nucleosidos y su uso como medicamentos inmunosupresores. - Google Patents

Nuevos esteres lipidicos de monofosfatos nucleosidos y su uso como medicamentos inmunosupresores.

Info

Publication number
MX9605809A
MX9605809A MX9605809A MX9605809A MX9605809A MX 9605809 A MX9605809 A MX 9605809A MX 9605809 A MX9605809 A MX 9605809A MX 9605809 A MX9605809 A MX 9605809A MX 9605809 A MX9605809 A MX 9605809A
Authority
MX
Mexico
Prior art keywords
hydrogen
oxygen
optionally substituted
carbon atoms
substituted alkyl
Prior art date
Application number
MX9605809A
Other languages
English (en)
Inventor
Dieter Herrmann
Hans-Georg Opitz
Harald Zilch
Alfred Mertens
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of MX9605809A publication Critical patent/MX9605809A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invencion se dirige a nuevos derivados de monofosfato de nucleosido de residuos de éster lipídico de formula general (I) (Ver Formula) en la que R1 puede ser una cadena alquilo opcionalmente sustituida que tiene 1-20 átomos de carbono; R2 representa hidrogeno, una cadena alquilo opcionalmente sustituida que tiene 1-20 átomos de carbono, R3, R4 y R5 representan hidrogeno, hidroxi, azido, amino, ciano o halogeno; X representa una valencia, oxígeno, azufre, un grupo sulfinilo o sulfonilo; Y representa una valencia, un átomo de oxígeno o de azufre; B representa una base purínica y/o pirimidínica; con la condicion de que por lo menos uno de los residuos R4 o R5 es hidrogeno; con sus tautomeros y sus sales fisiologicamente aceptables de ácidos y/o bases inorgánicas y orgánicas, así como con procesos para su preparacion y con drogas o medicamentos que contienen tales compuestos.
MX9605809A 1994-05-28 1995-05-23 Nuevos esteres lipidicos de monofosfatos nucleosidos y su uso como medicamentos inmunosupresores. MX9605809A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4418690A DE4418690A1 (de) 1994-05-28 1994-05-28 Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
PCT/EP1995/001951 WO1995032984A1 (en) 1994-05-28 1995-05-23 New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs

Publications (1)

Publication Number Publication Date
MX9605809A true MX9605809A (es) 1997-12-31

Family

ID=6519215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605809A MX9605809A (es) 1994-05-28 1995-05-23 Nuevos esteres lipidicos de monofosfatos nucleosidos y su uso como medicamentos inmunosupresores.

Country Status (27)

Country Link
US (1) US6025343A (es)
EP (2) EP0763049B1 (es)
JP (1) JP3802057B2 (es)
KR (1) KR100279087B1 (es)
CN (1) CN1168735C (es)
AT (2) ATE249472T1 (es)
AU (1) AU688516B2 (es)
BR (1) BR9507785A (es)
CA (1) CA2190983C (es)
CZ (1) CZ291846B6 (es)
DE (3) DE4418690A1 (es)
DK (2) DK1229040T3 (es)
ES (2) ES2199250T3 (es)
FI (1) FI117673B (es)
HU (1) HU220336B (es)
IL (1) IL113865A (es)
MX (1) MX9605809A (es)
NO (1) NO308998B1 (es)
NZ (1) NZ287434A (es)
PL (1) PL185290B1 (es)
PT (2) PT1229040E (es)
RU (1) RU2165429C2 (es)
SK (1) SK284207B6 (es)
TW (1) TW420686B (es)
UA (1) UA45339C2 (es)
WO (1) WO1995032984A1 (es)
ZA (1) ZA954374B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
JP3839857B2 (ja) * 1994-09-20 2006-11-01 塩野義製薬株式会社 エーテル型チオリン脂質化合物の製造方法
ES2206522T3 (es) * 1994-12-13 2004-05-16 Taiho Pharmaceutical Co., Ltd. Derivados de nucleosido sustituidos en 3'.
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
CN1216893C (zh) 1998-11-05 2005-08-31 法国国家科学研究中心 具有抗乙型肝炎病毒活性的核苷
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
DE19855963A1 (de) * 1998-12-04 2000-06-08 Herbert Schott Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
CA2390441A1 (en) 1999-11-08 2001-05-17 Origenix Technologies, Inc. Combinatorial library synthesis and pharmaceutically active compounds produced thereby
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002057498A1 (en) * 2001-01-22 2002-07-25 Emergen, Inc. Isotopically enriched nucleic acids and associated methods for the production and purification thereof
CN100400045C (zh) 2001-05-16 2008-07-09 米珍尼克斯公司 基于核酸的化合物及其使用方法
US20050090659A1 (en) * 2001-11-21 2005-04-28 Dieter Herrmann Phospholepid derivatives of nucleosides as antitumaorl medicaments
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
EP1835916B1 (en) 2004-12-30 2009-04-01 Medivir Ab Compounds useful in the treatment of hiv
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
EP1907407A1 (en) * 2005-07-22 2008-04-09 Giuliani International Limited Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation
ITRM20050391A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
EA019961B1 (ru) 2006-04-04 2014-07-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы
GB0608876D0 (en) 2006-05-05 2006-06-14 Medivir Ab Combination therapy
US7378401B2 (en) 2006-07-14 2008-05-27 Heidelberg Pharma Gmbh Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
CA2717788A1 (en) 2007-07-09 2009-01-15 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
UA119314C2 (uk) 2008-01-04 2019-06-10 Інтеллікіне Ллк Спосіб отримання похідних ізохінолінону (варіанти)
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EA201892769A3 (ru) 2013-03-15 2019-08-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Сложные диэфиры ациклических нуклеозидфосфонатов
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI657085B (zh) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 雜環化合物及其用途
ES2913486T3 (es) 2014-03-19 2022-06-02 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
DE102014112055A1 (de) * 2014-08-22 2016-02-25 Universität Hamburg Di- und Triphosphat-Propharmaka
PL3194411T3 (pl) 2014-09-15 2022-06-20 The Regents Of The University Of California Analogi nukleotydów
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930904A1 (de) * 1979-07-30 1981-02-19 Kailash Kumar Dr Gauri Verwendung von 5-alkyl-pyrimidinnucleosiden bei der bekaempfung von krebs
US4783402A (en) * 1983-04-11 1988-11-08 Meito Sangyo Kabushiki Kaisha Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
DE3612636C2 (de) * 1985-04-15 1993-11-18 Asahi Chemical Ind Nucleosid-Phospholipid-Komplexe
EP0262876B1 (en) * 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
JP2796089B2 (ja) * 1986-10-06 1998-09-10 旭化成工業株式会社 リン脂質誘導体の製造法
DE3730542A1 (de) * 1987-09-11 1989-04-06 Hoechst Ag Arzneimittel mit einem gehalt an bestimmten 6-mercaptopurin-derivaten, verwendung dieser 6-mercaptopurin-derivate, verfahren zur herstellung der arzneimittel sowie einige neue 6-mercaptopurin-derivate und verfahren zu deren herstellung
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE4026265A1 (de) * 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5563257A (en) * 1990-08-20 1996-10-08 Boehringer Mannheim Gmbh Phospholipid derivatives of nucleosides
DE4111730A1 (de) * 1991-04-10 1992-10-15 Knoll Ag Neue cytarabin-derivate, ihre herstellung und verwendung
DE4204032A1 (de) * 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates

Also Published As

Publication number Publication date
AU2615495A (en) 1995-12-21
DE69530197D1 (de) 2003-05-08
WO1995032984A8 (en) 2003-01-16
EP0763049A1 (en) 1997-03-19
ATE249472T1 (de) 2003-09-15
PT1229040E (pt) 2003-12-31
DE69531749D1 (de) 2003-10-16
EP1229040B1 (en) 2003-09-10
FI117673B (fi) 2007-01-15
ES2199250T3 (es) 2004-02-16
CZ347796A3 (en) 1997-04-16
EP1229040B8 (en) 2003-11-05
NZ287434A (en) 1998-01-26
SK284207B6 (en) 2004-11-03
WO1995032984A1 (en) 1995-12-07
PT763049E (pt) 2003-08-29
NO965054D0 (no) 1996-11-27
ES2206429T3 (es) 2004-05-16
DE4418690A1 (de) 1996-01-11
EP1229040A3 (en) 2002-08-21
BR9507785A (pt) 1997-09-23
DE69531749T2 (de) 2004-07-29
IL113865A (en) 2008-12-29
ZA954374B (en) 1996-11-29
FI964727A0 (fi) 1996-11-27
CA2190983C (en) 2006-08-15
DK1229040T3 (da) 2003-12-22
CN1154111A (zh) 1997-07-09
PL185290B1 (pl) 2003-04-30
ATE236189T1 (de) 2003-04-15
JPH10500964A (ja) 1998-01-27
EP0763049B1 (en) 2003-04-02
UA45339C2 (uk) 2002-04-15
US6025343A (en) 2000-02-15
SK151896A3 (en) 1997-06-04
NO308998B1 (no) 2000-11-27
TW420686B (en) 2001-02-01
HU220336B (hu) 2001-12-28
IL113865A0 (en) 1995-08-31
HU9603269D0 (en) 1997-01-28
PL317380A1 (en) 1997-04-01
JP3802057B2 (ja) 2006-07-26
AU688516B2 (en) 1998-03-12
RU2165429C2 (ru) 2001-04-20
HUT75340A (en) 1997-05-28
CA2190983A1 (en) 1995-12-07
KR970703354A (ko) 1997-07-03
CN1168735C (zh) 2004-09-29
DK0763049T3 (da) 2003-07-28
CZ291846B6 (cs) 2003-06-18
EP1229040A2 (en) 2002-08-07
DE69530197T2 (de) 2004-01-29
FI964727A (fi) 1996-11-27
NO965054L (no) 1997-01-28
KR100279087B1 (ko) 2001-01-15

Similar Documents

Publication Publication Date Title
MX9605809A (es) Nuevos esteres lipidicos de monofosfatos nucleosidos y su uso como medicamentos inmunosupresores.
KR880013967A (ko) 항비루스 화합물
LU91348I9 (es)
BR0011521A (pt) Composto nucleósidos de purina de 4' -c-etinila
HU902839D0 (en) Process for producing acriloyl-substituted pyrrole derivatives and pharmaceutical preparatives containing them
ES2014482B3 (es) Nuevas 2-tiazolil imidazo/1,2-a/pirimidinas y sus sales, su procedimiento de preparacion, su aplicacion a titulo de medicamentos y las composiciones que las encierran.
ES2013379A6 (es) Procedimiento para preparar 6-sulfenamido-6, sulfinamido- y 6-sulfonamido-purinas, nucleosidos de purinas y nucleotidos de purinas antitumorales.
ES2057031T3 (es) Compuestos de nucleosido de 2'-metilidenpirimidina, su uso y metodo para su produccion.
AU7653300A (en) Carbocyclic nucleosides and process for obtaining such
ATE198746T1 (de) Pyrimidinderivate und pharmazeutische zusammensetzungen
ES2037401T3 (es) Procedimiento para preparar derivados de nucleosidos.
AR003454A1 (es) Derivados de nucleosido de pirimidina, un procedimiento para su preparación y el uso de los mismos como agentes antivirales.
ES2061864T3 (es) Sustancia antitumoral, procedimiento para su preparacion, y agente anticanceroso que la contiene.
CY1117836T1 (el) Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: HEIDELBERG PHARMA HOLDING GMBH

MM Annulment or lapse due to non-payment of fees